Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 5Lymphoid 5CNS 3Thoracic 2Sarcoma 2Other hematologic neoplasm 1

Conditions

Sarcoma 317Gastrointestinal Stromal Tumors 108Neoplasms 105Breast Neoplasms 92Melanoma 81Ovarian Neoplasms 79Neoplasm Metastasis 74Carcinoma, Non-Small-Cell Lung 74Colorectal Neoplasms 70Osteosarcoma 61Stomach Neoplasms 59Pancreatic Neoplasms 55Bone Neoplasms 55Prostatic Neoplasms 51Head and Neck Neoplasms 48Glioblastoma 48Sarcoma, Ewing 47Lung Neoplasms 45Esophageal Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Carcinoma, Renal Cell 40Uterine Cervical Neoplasms 39Sarcoma, Kaposi 38Lymphoma 37Urinary Bladder Neoplasms 36Sarcoma, Synovial 36Recurrence 35Dendritic Cell Sarcoma, Interdigitating 34Lymphoma, Non-Hodgkin 33Endometrial Neoplasms 33

Interventions

repotrectinib 1ceritinib 1Suspensions 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Granuloma, Plasma Cell × Sarcoma × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡